Hereโs Why Cencora (COR) Shares Rose 8% in Q4 - Insider Monkey
๐ Cencora (COR) shares rose 8% in Q4 as fiscal fourth-quarter earnings outpaced consensus estimates.
๐ฐ Consolidated revenue for the first quarter of fiscal 2026 increased 5.5% year-over-year to $85.9 billion.
๐ข Management announced it is considering strategic alternatives for animal health and non-core PharmaLex business units.
๐ The stock closed at $331.74 per share on March 19, 2026, with a market cap of $64.5 billion.
๐ Hedge fund holdings increased to 61 portfolios in Q4 2025, up from 59 in the prior quarter.
๐ค TimesSquare Capital prefers AI stocks over Cencora for delivering higher returns and shorter timeframes.
๐ International business missed estimates, though U.S. strength offset this weakness during the quarter.
Bullish Signals
- Cencora's fiscal Q4 earnings exceeded consensus estimates, demonstrating operational resilience.
- The company achieved a 5.5% year-over-year revenue increase in Q1 fiscal 2026 to $85.9 billion.
- U.S. business strength successfully offset a miss in international operations during the quarter.
- Hedge fund interest is growing, with portfolio holdings increasing from 59 to 61 in Q4 2025.
- The stock gained 8% in Q4 and has delivered a 24.05% return over the past 52 weeks.
Risk Factors
- International business operations missed consensus estimates, indicating regional weakness.
- TimesSquare Capital explicitly states that AI stocks hold greater promise for higher returns than Cencora.
- Management is considering strategic alternatives for animal health and non-core PharmaLex segments, which could signal a shift in focus or potential asset divestiture.
Full Analysis
TimesSquare Capital Management released its fourth-quarter 2025 investor letter, highlighting Cencora (NYSE: COR) as a preferred healthcare holding. The firm noted that Cencora's shares gained 8% in the quarter, driven by fiscal Q4 earnings that outpaced consensus estimates due to strength in U.S. operations offsetting an international miss. Management also announced it is considering strategic alternatives for the animal health and non-core segments of its PharmaLex business.
Cencora, a pharmaceutical sourcing and distribution company, closed at $331.74 per share on March 19, 2026, with a market capitalization of approximately $64.5 billion. In the first quarter of fiscal 2026, consolidated revenue increased 5.5% year-over-year to $85.9 billion, reflecting solid growth across both reportable segments. The company is currently held by 61 hedge fund portfolios, an increase from 59 in the previous quarter.
Despite the positive performance and earnings beat, TimesSquare Capital expressed a preference for AI stocks over Cencora for delivering higher returns within a shorter timeframe. While acknowledging the risk and potential of Cencora, the firm believes other sectors may offer superior upside. The article concludes with promotional links to other investment strategies and subscription offers from Insider Monkey.